Kymera Therapeutics Inc. (KYMR): Price and Financial Metrics
KYMR Price/Volume Stats
| Current price | $33.37 | 52-week high | $45.31 |
| Prev. close | $33.35 | 52-week low | $9.60 |
| Day low | $33.22 | Volume | 452,300 |
| Day high | $34.14 | Avg. volume | 730,110 |
| 50-day MA | $38.86 | Dividend yield | N/A |
| 200-day MA | $25.64 | Market Cap | 2.05B |
KYMR Stock Price Chart Interactive Chart >
Kymera Therapeutics Inc. (KYMR) Company Bio
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Latest KYMR News From Around the Web
Below are the latest news stories about KYMERA THERAPEUTICS INC that investors may wish to consider to help them evaluate KYMR as an investment opportunity.
Kymera Therapeutics Has Doubled in 2 Months, But Is the Upside Sustainable?Kymera Therapeutics is a clinical stage biopharmaceutical company focused on "discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system." The clinical stage business is expensive and risky, so let's check out a few charts and indicators for some guidance on the stock. The On-Balance-Volume (OBV) line has moved upwards since October telling me that buyers of KYMR have been more aggressive than sellers. |
12 Most Promising Cancer Stocks According to AnalystsIn this piece, we will take a look at the 12 most promising cancer stocks according to analysts. If you want to skip our overview of the latest trends in the cancer treatment sector, then you can take a look at the 5 Most Promising Cancer Stocks According to Analysts. The advent of technology and […] |
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 34% Share Price Surge Not Quite Adding UpThe Kymera Therapeutics, Inc. ( NASDAQ:KYMR ) share price has done very well over the last month, posting an excellent... |
We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4Company to provide update on its emerging pipeline of high-value immunology programsWATERTOWN, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared webcast information for the virtual Immunology R&D Day that the Company will host on January 4, 2024, from 10:00 a.m. to 12:00 p.m. ET. The R&D Day will focus on the Company’ |
KYMR Price Returns
| 1-mo | -16.99% |
| 3-mo | 7.58% |
| 6-mo | 197.42% |
| 1-year | 5.80% |
| 3-year | -25.88% |
| 5-year | N/A |
| YTD | 31.07% |
| 2023 | 2.00% |
| 2022 | -60.69% |
| 2021 | 2.40% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...